CitiusTech Acquires Health Data Movers, Enhances Healthcare Provider Offerings With Epic Implementation Capabilities
PRINCETON, N.J. — CitiusTech, a leading provider of healthcare technology, services & solutions, today announced that it has acquired Health Data Movers, a Best in KLAS healthcare technology services firm, with deep expertise in Epic Systems, Workday, ServiceNow and other core healthcare platforms.
Article content
As healthcare providers work to improve quality of care and deliver more connected patient and clinician experiences, they face the challenges of unifying complex technology ecosystems while accelerating innovation. The rapid rise of Agentic AI, Cloud, and AI Scribes has only heightened the need for seamless integration into the core systems clinicians and staff use every day. Epic, as the digital backbone of many healthcare providers, has been central to this transformation, driving digital adoption, enabling interoperability, and opening new pathways to embed advanced analytics and AI directly into clinical workflows.
Article content
The combination of CitiusTech's AI, data, and automation solutions and Health Data Movers' deep integration expertise, creates a unique ability to embed intelligence and automation directly into core operational platforms such as EMR, ITSM and ERP. By bringing advanced digital capabilities directly into the daily workflows that health systems trust, this approach minimizes change management risks, and delivers scalable, end-to-end solutions that enable Providers to achieve greater efficiency, quality, and impact in patient care.
Article content
'This is a pivotal moment and huge opportunity for CitiusTech and Health Data Movers, as we meet the demands of a rapidly transforming healthcare landscape. By combining forces, we are redefining the path to seamless integration, and infusing AI and intelligent automation into clinical operations. Together, we empower our customers to unlock transformative efficiencies, deliver connected patient care, and accelerate innovation, all within the systems they trust. This partnership strengthens CitiusTech's position as a strategic partner across the healthcare ecosystem,' said Rajan Kohli, CEO, CitiusTech. By bringing Health Data Movers' Epic implementation and integration expertise into CitiusTech's portfolio, this partnership has the ability to operate at the very core of the Epic ecosystem, solving some of healthcare's most critical challenges.
Article content
'At Health Data Movers, our commitment has always been to empower patients and providers by harnessing the potential of data and technology,' said Tyler Smith, CEO, Health Data Movers. 'Joining forces with CitiusTech allows us to pair that expertise with unmatched scale, advanced technologies, and expanded capabilities. Together, we can deliver future-ready solutions, that not only improve patient outcomes and lower costs, but also redefine how patients and providers fully benefit in an AI-powered healthcare ecosystem.'
Article content
CitiusTech and Health Data Movers share a vision of advancing healthcare through human-centered technology, operational excellence, and trusted partnerships.
Article content
Founded in 2012, Health Data Movers is a US-based, specialized healthcare IT services firm, with a mission to empower patients and Providers by unleashing the potential of healthcare data and technology. They are trusted partners to healthcare organizations, biotechnology companies, and digital health enterprises, delivering unique, data-driven solutions through their Data Management, Integration, Project Management and Clinical & Business Applications services. Health Data Movers brings with it a highly skilled team of healthcare technology professionals with deep expertise in large-scale EMR program delivery, clinical workflows, and operational transformation.
Article content
Health Data Movers was advised on this transaction by Equiteq.
Article content
About CitiusTech
Article content
CitiusTech
Article content
is a global technology services, consulting, and business solutions enterprise 100% focused on the healthcare and life sciences industry. We enable 140+ enterprises to build a human-first ecosystem that is efficient, effective, and equitable. Leveraging deep domain expertise and next-generation technologies including AI, Cloud, Data, and Intelligent Automation, we assist our clients in realizing their vision, accelerate transformation, and achieve business outcomes. With over 8,500 healthcare technology professionals worldwide, CitiusTech powers digital innovation, business transformation, and industry-wide convergence through next-generation technologies, solutions, and products. Follow CitiusTech on
Article content
.
Article content
Health Data Movers
Article content
(HDM) is a 'Best in KLAS' healthcare technology services firm. They are trusted partners to healthcare organizations, biotechnology companies, and digital health enterprises through their Services – Data Management, Integration, Project Management, and Clinical & Business Applications – they are the smart choice for creating unique solutions that empower patients and providers by unleashing the potential of healthcare data and technology. Recognized as a leader in the industry, HDM has been named to the Inc. 5000 list six times (2020, 2021, 2022, 2023, 2024, 2025). Additionally, HDM was honored as one of the 'Best Firms to Work For' by Consulting Magazine in 2020 and 2025.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 minutes ago
- Globe and Mail
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
AbbVie 's ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter. AbbVie announced its second-quarter results on July 31. It beat estimates for both earnings and sales. Earnings of $2.97 per share rose 12.1% year over year. Revenues of $15.42 billion rose 6.6% year over year on a reported basis, driven by robust sales of key drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs, namely Ubrelvy, Elahere, Epkinly and Qulipta. Sales of Humira and Imbruvica declined year over year. AbbVie also raised its revenue and EPS guidance for 2025 for the second time this year, backed by a strong momentum in the first half. The company expects adjusted EPS to be in the range of $11.88-$12.08, up from the previous guidance of $11.67-$11.87. Total revenues are expected to be approximately $60.5 billion, higher than the previous expectation of $59.7 billion. However, a single quarter's results are not so important for long-term investors, and the focus should rather be on the company's strong fundamentals. Let's understand the company's strengths and weaknesses to better analyze how to play ABBV stock amid the post-earnings price gain. ABBV's Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for its blockbuster drug, Humira, in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to loss of exclusivity ('LOE') and biosimilar erosion. However, AbbVie has successfully navigated the LOE of Humira by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and are expected to support top-line growth in the next few years. Sales of Skyrizi and Rinvoq have successfully replaced Humira, which once generated more than 50% of its total revenues. Skyrizi and Rinvoq generated combined sales of $11.6 billion in the first half of 2025. The drugs are seeing strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn's disease (CD). Importantly, Skyrizi and Rinvoq have demonstrated compelling head-to-head data against several novel therapies in clinical studies, which have given them a competitive advantage. Skyrizi sales are now annualizing at almost $18 billion and Rinvoq at over $8 billion. AbbVie expects combined sales of Skyrizi and Rinvoq to be more than $25 billion in 2025 and more than $31 billion by 2027(Skyrizi: more than $20 billion; Rinvoq: more than $11 billion). Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' growth. AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication later this year. In addition, phase III data with Rinvoq in vitiligo are expected later in 2025, followed by hidradenitis suppurativa and systemic lupus erythematosus Phase III readouts in 2026. AbbVie believes that the next wave of potential approvals for Rinvoq could add roughly $2 billion to peak-year sales for the product. ABBV's Growing Oncology Portfolio AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta. Its oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offset the decline in Imbruvica sales. Some key oncology drugs approved in the past couple of years are Epkinly and Emrelis. Elahere was added to AbbVie's oncology portfolio with the February 2024 acquisition of Immunogen. AbbVie is also strengthening its portfolio of oncology medicines with the addition of antibody-drug conjugates or ADCs, which are being considered a disruptive innovation in the pharmaceutical industry. ADCs will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. The company now has two ADCs in its commercial portfolio (i.e., Elahere and Emrelis) and two additional ADCs in late-stage development (ABBV-400 and pivekimab sunirine), along with some others in early-stage development. AbbVie's neuroscience portfolio is also contributing to top-line growth. Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta. AbbVie on an Acquisition Spree AbbVie has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline that should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas. AbbVie has executed more than 30 M&A transactions since the beginning of 2024. A key deal was the April 2025 licensing agreement with Denmark's Gubra to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity. The deal marked AbbVie's entry into the obesity space, dominated by Eli Lilly LLY and Novo Nordisk NVO. AbbVie plans to invest further in obesity. AbbVie recently closed the acquisition of privately held biotech Capstan Therapeutics, which will add Capstan's lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to its immunology pipeline. ABBV's Slowing Aesthetics Sales & Humira Erosion Sales of AbbVie's blockbuster drug Humira are declining due to biosimilar erosion. The launch of Humira biosimilars in the United States in 2023 significantly eroded the drug's sales in 2024, with the decline being sharper in 2025 as more plans excluded branded Humira and moved to exclusive biosimilar contracts. Humira sales declined more than 50% in the first half of 2025. AbbVie expects Humira's access in the United States to continue to decrease through the second half as more plans select exclusionary formularies for existing patients. AbbVie is seeing declining sales of Juvederm fillers due to continued macro challenges and weakened consumer sentiment. The slowing growth of the U.S. facial injectables market and persistent economic headwinds, which are impacting consumer spending in some countries, including the United States, are hurting sales of Juvederm due to its higher price point. Juvederm sales declined 22.2% in the first half of 2025. ABBV Stock Price, Valuation and Estimate Revision AbbVie's stock has gained 19.3% so far this year against a decrease of 1.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. ABBV Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, AbbVie is not very cheap. Going by the price/earnings ratio, the company's shares currently trade at 15.31 forward earnings, higher than 14.46 for the industry. The stock is cheaper than some other large drugmakers like Eli Lilly, AstraZeneca and J&J, but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.68. ABBV Stock Valuation The Zacks Consensus Estimate for 2025 earnings has declined from $12.03 per share to $12.02, while that for 2026 has increased from $14.08 to $14.31 per share over the past 30 days. ABBV Estimate Movement Stay Invested in ABBV Stock Though AbbVie faces its share of near-term headwinds, the company has faced its biggest challenge — Humira's patent cliff — quite well and looks well-positioned for continued strong growth in the years ahead. AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform. Sales of AbbVie's ex-Humira drugs rose more than 22% (on a reported basis) in the quarter, driven by Skyrizi, Rinvoq and neuroscience drugs. Boosted by its new product launches, AbbVie expects to return to mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as the company has no significant LOE events for the rest of this decade. A substantial portion of this growth is expected to be driven by the robust performance of Skyrizi and Rinvoq. With no significant LOEs in this decade, AbbVie enjoys the flexibility to invest more in R&D to continue to acquire external innovation. Rising stock price and estimates (for 2026), its solid pipeline and the fact that it is entering the second half of the year with substantial momentum are good enough reasons to stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
Globe and Mail
3 minutes ago
- Globe and Mail
Market Factors: Natural gas setup looks really promising
In this edition of Market Factors we start with why the depressed natural gas sector may turn out to be a huge opportunity. In part two, a prominent strategist is seeing cracks in the megacap market leadership. And the diversion looks at my favourite movie soundtracks. I've been touting the growth story in natural gas while the commodity price hovers near 25-year lows, so I suppose I owe readers an explanation. I not only believe in the story, but also think things are progressing in a way that will be extremely lucrative for investors if the 2026 demand outlook unfolds as predicted. Natural gas production has significantly exceeded demand this year and this successfully smothered the commodity price. The current end of summer inventory levels are close to record highs thanks to year-to-date production increases of over a billion cubic feet per day. On Tuesday, BofA Securities commodity strategist Clifton White wrote that since 2019, Western Canada natural gas demand growth has come almost exclusively from industrial companies and utilities. Demand from these sources has flagged, increasing oversupply conditions. Now for the good news for investors. Historically the only outlets for domestic natural gas production were pipelines flowing to the U.S. and Eastern Canada. Now, however, the LNG Canada facility on the B.C. coast is operational and gives Canadian gas producers access to global markets. Mr. White believes that LNG Canada 'will cause Western Canada inventories to flip from near record highs this fall to near 10-years lows by the end of summer 2026 [and this] … will lead to stronger AECO prices and fewer Canadian exports to the U.S. next year.' For the natural gas sector, business conditions are bad now and forecast to get much better next year. Theoretically, an investor might be able to find a related stock at depressed prices now, and benefit as conditions improve. We should have a few months of research to attempt to uncover this opportunity. The accompanying table using RBC Capital Markets data can provide a guide to further study. Each stock's leverage to gas prices, valuations in terms of enterprise value to debt-adjusted cash flow and recent performance are included. As always, there are risks for investors. Global natural gas demand, operational issues at LNG Canada and excess production are only three potential events that could screw up this potentially profitable trade. It is still worth further study in my opinion. Megacap stocks have dominated markets since 2015 but one strategist now sees cracks in the trend. A shift in the market cycle from a downturn stage into recovery means smaller cap stocks will retake market leadership, according to BofA's Savita Subramanian. Ms. Subramanian grouped the S&P 500 into deciles and noted that the last Nifty Fifty run – significant outperformance by the largest 50 companies – occurred in the late 1990s. Back then, the outperformance lasted six years and the largest companies outperformed the broader benchmark by 71 percentage points. Currently the biggest 50 stocks have outperformed the benchmark by 73 percentage points since 2015. The average balance sheet quality of today's top 50 is well below the late 1990s. Average valuations are near record highs while growth expectations are, despite the substantial growth forecasts for the magnificent seven, unspectacular overall. The switch to a recovery market cycle historically means that economically sensitive, higher beta (market sensitivity), smaller market cap stocks outperform. Ms. Subramanian expects stocks with lower valuations (in terms of forward PE ratios), above median beta, below median market cap and buy-rated at BofA to outperform. Her screen by these factors uncovered United Airlines Holdings Inc., Halliburton Co., Expedia Group Inc. and lululemon athletica Inc. The MakeUseOf site posted their picks for most underrated movie soundtracks and there are some interesting selections. I hadn't thought of The Last American Virgin as having great music but on review the soundtrack looks great. My picks for favourite soundtracks begin with John Hughes movies, notably the Eric Stoltz and Mary Stuart Masterson classic Some Kind of Wonderful. The Flesh for Lulu song I Go Crazy seals it for Some Kind of Wonderful because that song was impossible to find at the time. (The phenomenon of being completely unable to listen to a song you like must be inexplicable to modern generations. Led Zeppelin's Say Hey Woman was another example). Classics like Wizard of Oz and Singin' in the Rain must be mentioned when the soundtrack topic comes up. For the '80s Purple Rain and then in the '90s there's Singles. The High Fidelity soundtrack is quirky and amazing. Donnie Darko, Trainspotting, Grease, Saturday Night Fever are all notable. I just thought of The Commitments for the first time in at least 25 years because of its terrific and timeless music. What are your favourites? Looking for our updates on market movers, analyst actions, stock technicals, insider trades and other daily, weekly and monthly insight? Click here to visit our Inside the Market page. A look at how this week's inflation report has shifted market and economist views for future Bank of Canada rate cuts The latest Reuters polling of equity strategists and portfolio managers finds a bullish bunch when it comes to the TSX - but less so for the S&P 500 Jamie McGeever takes a closer look at how markets and Donald Trump are in a delicate policy dance Reuters' Ron Buosso on why the Ukraine outcome is insignificant for oil markets The data calendar starts with industrial product prices for July on Thursday when economists expect a 0.3 per cent month-over-month increase. Retail sales for June follows the next day and consensus is looking for a 1.5 per cent rise for the headline number and 0.8 per cent jump ex-autos. Bank earnings are the highlight for Canadian investors in the coming week. Bank of Montreal ($2.942 per share expected) and Bank of Nova Scotia ($1.73) report Tuesday. Royal Bank ($3.317) and National Bank ($2.675) post numbers Wednesday. Dollarama ($1.152) also reports next Wednesday. American economic data of importance begins Thursday with S&P Global U.S. Manufacturing PMI (49.7 expected), which provides an early look at August results. The leading index for July (-0.1 per cent month over month) is also out Thursday but that index has been providing deceptively negative results of late. Preliminary durable goods orders for July (-4.0 per cent month over month) will be released next Tuesday. We'll get corporate results from Walmart Inc. ($0.733) on Thursday and the 27th will see earnings reports from Crowdstrike Holdings Inc. ($0.832) and the big one, Nvidia Corp. ($1.005). See our full earnings and economic calendar here
CBC
4 minutes ago
- CBC
TikTok Canada is closing soon. The Beaches and bbno$ warn it will hurt homegrown artists
In 2021, a TikTok of Canadian rapper bbno$ raising his eyebrows to the beat of his single "Edamame" started gaining traction — and eventually changed the course of his career. The platform's Canadian team suggested he recreate the clip with a safari-themed filter, then helped push it globally. "When that happened, the song just skyrocketed," he says of the track, which features Indonesian rapper Rich Brian and went six-times Platinum in various countries. bbno$ is among several Canadian artists worried about losing social media support that can make or break their careers as TikTok prepares to comply with a federal order to shut down its operations in Canada. For Canadian musicians, TikTok can be as vital as radio play once was. Its algorithm lets songs leap borders instantly, offering emerging acts — especially racialized artists facing barriers in traditional channels — a shot at global reach. With Ottawa's dissolution order set to take effect soon, TikTok Canada's team has been running campaigns to show its value — and Canadian artists are rallying behind them. "Being an artist in this generation is like, you're basically a TikTokker," says the Juno-winning rapper, born Alexander Gumuchian. "Without having a TikTok team that I can relay information to — that could help me get banners, help me when things are starting to bubble — I'm losing ammunition to help fire my career up." Concerns around access to user data behind government's move In November 2024, Ottawa ordered TikTok's Canadian arm to dissolve following a national security review of its Chinese parent company, ByteDance Ltd., though the app will remain accessible in Canada. The order cited "national security risks" but a government spokesperson declined to provide specifics due to "confidentiality provisions." Social media researcher Philip Mai says there are concerns around potential Chinese government access to user data, foreign surveillance of Canadians in sensitive sectors and misuse of information for propaganda. "China's National Intelligence Law legally permits data access, raising plausible risk concerns," says the co-director of the Social Media Lab at the Ted Rogers School of Management. Canada has ordered TikTok's offices closed. Should you still be on the app? 10 months ago The federal government has ordered TikTok to close its offices in Canada because of national security concerns. CBC's Ashley Fraser explains what we know and don't know about that risk. Still, no public evidence shows TikTok has shared user data with the Chinese government, and the company denies it. Mai says shutting down TikTok Canada reduces its physical and legal presence in the country, limiting the platform's potential for data surveillance and its ability to influence policy or public opinion. "This strategy is less extreme than banning TikTok, but more than a slap on the wrist," he says. bbno$ says the platform's Canadian team has helped bolster his social media presence. Without it, he warns, many Canadian artists will face a "bottleneck" in their careers. Juno-winning Toronto band The Beaches says TikTok Canada has been "instrumental" in their rise. "Without local teams championing Canadian musicians internationally, we're left competing with American artists as outsiders, not as domestic talent," says the group in a statement. "This puts us at a disadvantage and pushes Canadian artists to leave the country just to have a shot at global success." Though The Beaches have enjoyed Canadian radio airplay for years, their single "Blame Brett" went viral on TikTok in 2023, helping them reach the U.S. Billboard charts for the first time. Mai warns TikTok Canada's closure would be a "big blow to Canadian artists," reducing opportunities, support systems, grant programs and sponsorships. "Forcing the closure of TikTok's Canadian operation will likely decrease Canadian visibility in the algorithm," he says, noting local staff often boost regional content via tailored campaigns, including ones highlighting Indigenous creators. Last month, TikTok CEO Steven Chew asked Minister of Industry Melanie Joly for an urgent meeting, warning that shutting down TikTok Canada would force layoffs, halt investments and pull support from creators and culture. "The wind-up process is rapidly approaching a critical juncture," Chew wrote. TikTok declined to provide a date and to say whether it has heard back from Joly, who did not respond to questions about the meeting request. Loss for racialized alum of TikTok's Accelerator program, creators say The platform recently withdrew sponsorships for several Canadian arts institutions, including the Juno Awards and TIFF, and slashed the National Screen Institute's TikTok Accelerator for Indigenous Creators, which has supported nearly 400 participants since 2021. Indigenous hoop dancer James Jones says the federal government's shutdown order shows a disregard for the country's digital creators. "It's really unfortunate that they are taking away a team that has been so supportive of the BIPOC community and the Indigenous community," says the Edmonton-based creator, who boasts over four million followers. "I don't think that anyone has ever asked us what we wanted or even reached out and said, `Hey, how is this going to affect you?"' Jones says early in his career, TikTok Canada offered advice on maximizing his reach and facilitating key connections with brands and publications. He says its Accelerator program has helped many Indigenous creators and small businesses. Jones feels the government is sending a message that "we're not being prioritized." "They don't care what happens to us, they don't care about our businesses, our brands," he says. "They don't care about how it affects us personally to not have access to a team that supports us directly." Vanessa Brousseau, an advocate for missing and murdered Indigenous people, says the government's decision feels "really painful, but familiar." "It feels like a pattern and a way of oppressing minorities, oppressing Indigenous people," says the alum of the TikTok Accelerator for Indigenous Creators. "TikTok is the only platform that amplifies our voices and makes sure we're being heard." Brousseau worries that if the decision isn't reversed, it will be "very detrimental" to Indigenous TikTok creators.
